CDC-RFA-IP21-2107: Partnering with Professional and Medical Associations to Increase Vaccination Coverage Across Different Racial and Ethnic Adult Populations Experiencing Disparities
Closed
This grant is closed. A newer notice from the same program is forecast: Informing global polio eradication efforts through innovative modeling approaches (CDC-RFA-JG-27-0077). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - NCIRD notices from 2021.
Centers for Disease Control - NCIRD offered grants to nonprofits. It expected to make about 3 awards worth $1.0 million in total. Applications closed on January 19, 2021.
From the official notice on Grants.gov, last changed January 6, 2021. Checked November 7, 2026.
- Total funding$1.0 million
- Expected awards3
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | January 6, 2021 |
|---|---|
| Deadline | January 19, 2021 |
| Archived by Grants.gov | February 18, 2021 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
National Medical Association (NMA) National Hispanic Medical Association (NHMA) National Black Nurses Association (NBNA) Association of American Indian Physicians (AAIP) National Council of Urban Indian Health (NCUIH) If the application is incomplete, late or does not address the requirements listed in this NOFO, it will be considered non-responsive and will not be entered into the review process.
Is this a realistic fit?
- Most of the program's money (47% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
CDC seeks to build the evidence base of effective interventions to improve vaccination coverage and to identify and implement strategies to reduce racial and/or ethnic disparities in adult vaccination coverage. A strong recommendation from a healthcare provider is the single most important factor in vaccine acceptance as they are seen as trusted agents on vaccine-related issues for patients, especially if the provider is of the same racial or ethnic minority group as the patient. To improve vaccine confidence and coverage among certain racial and ethnic groups, CDC aims to increase the likelihood that providers, particularly providers of color, will recommend vaccination to patients from these racial and ethnic groups. Develop strategies and resources for individual clinicians providing health care: Develop, implement, and disseminate strategies and resources to address clinicians’ roles in reducing racial and/or ethnic disparities in adult vaccination coverage (e.g., racial and health equity messaging, trainings, and materials) Develop strategies and resources for health care organizations: Develop, implement, and disseminate strategies and resources to address the health care organizations’ role in reducing racial and/or ethnic disparities in adult vaccination coverage (e.g., recommended processes or practical guidance to members for improving equity in vaccine administration) Enhance the resource and evidence base: Collaborate with the Learning Hub, Data Hub, and Media Center to review, modify, and improve resources
Who has won Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects grants before
From fiscal 2021 to 2025, Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects (93.185) awarded $857 million across 243 grant awards, an average of $3.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Unicef | New York | 2 | $133 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 2 | $74.7 million |
| Community Catalyst Inc | Massachusetts | 1 | $39.4 million |
| Pan American Health Organization | District of Columbia | 3 | $21.9 million |
| Unidosus | District of Columbia | 1 | $18.6 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0077, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-IP21-2107 still open?
No. It closed on January 19, 2021. A newer notice is forecast: CDC-RFA-JG-27-0077, expected deadline February 12, 2027.
Who can apply for Partnering with Professional and Medical Associations to Increase Vaccination Coverage Across Different Racial and Ethnic Adult Populations Experiencing Disparities?
Centers for Disease Control - NCIRD accepted applications from nonprofits. The notice adds further conditions, so read its eligibility section.
What is the deadline for Partnering with Professional and Medical Associations to Increase Vaccination Coverage Across Different Racial and Ethnic Adult Populations Experiencing Disparities?
Closed January 19, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $1.0 million in total across about 3 awards.
Who has won Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects grants before?
The largest recipients over five fiscal years were Unicef, National Foundation for the Centers for Disease Control & Prevention, Inc., Community Catalyst Inc. The program made 243 awards worth $857 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)